Clinic
Cook Children's Medical Center
Cook Children's Medical Center was paid $286.65M by Medicaid between Dec 2019 and Dec 2024, across 238 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoCOOK CHILDREN'S MEDICAL CENTER
FORT WORTH, TX 76104
FORT WORTH, TX 76104
33aNPI1891765178assigned 01/26/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$286.65M
24GClaims1,086,550
24DCodes billed238
24AFirst – last monthDec 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#1 of 320
Median peer was paid$205K
This provider vs. median1,399×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RHOADES, CORY controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 707 | $44K | |
| 2020 | 28,253 | $5.59M | |
| 2021 | 266,878 | $62.45M | |
| 2022 | 309,887 | $82.96M | |
| 2023 | 296,263 | $84.97M | |
| 2024incomplete | 184,562 | $50.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 42,589 | 41,652 | $70.09M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 29,231 | 28,256 | $51.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 72,904 | 71,913 | $46.52M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 83,958 | 82,773 | $30.80M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 5.3% | 6,887 | 6,639 | $15.11M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.9% | 181,005 | 165,471 | $8.38M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 29,606 | 29,253 | $5.87M |
| G0378 | Hospital observation service, per hour | 1.6% | 2,757 | 1,362 | $4.60M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.6% | 5,569 | 745 | $4.46M |
| 87631 | 1.4% | 24,377 | 23,960 | $4.10M | |
| 93000 | 1.4% | 16,712 | 16,056 | $3.89M | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 12,955 | 9,321 | $3.66M |
226 more codes
| 93325 | 1.2% | 6,851 | $3.49M | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.2% | 5,543 | $3.46M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.0% | 1,802 | $2.95M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 50,285 | $2.92M |
| 93320 | <1% | 5,607 | $2.49M | |
| 94010 | <1% | 5,294 | $1.75M | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 36,315 | $1.62M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,432 | $1.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 12,527 | $1.37M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 356 | $1.37M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,697 | $1.28M |
| 76770 | <1% | 5,389 | $766K | |
| 87506 | <1% | 2,190 | $663K | |
| 74018 | <1% | 15,737 | $622K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,088 | $508K |
| 92567 | <1% | 12,466 | $502K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,265 | $484K |
| 84145 | <1% | 14,766 | $451K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 288 | $409K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 215 | $381K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,768 | $377K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,143 | $368K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 17,084 | $349K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 4,663 | $348K |
| 80053 | Comprehensive metabolic panel | <1% | 26,929 | $334K |
| 96137 | <1% | 351 | $328K | |
| 92579 | <1% | 2,986 | $316K | |
| 86141 | <1% | 21,121 | $310K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,334 | $294K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 5,238 | $287K |
| 87428 | <1% | 3,994 | $284K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 29,465 | $282K |
| J3490 | Unclassified drugs | <1% | 4,669 | $269K |
| 44970 | <1% | 56 | $257K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 4,456 | $253K |
| 96116 | <1% | 629 | $226K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 141 | $198K |
| 87040 | <1% | 15,793 | $191K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,268 | $181K |
| 96133 | <1% | 308 | $176K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,060 | $162K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 162 | $152K |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 9,520 | $143K |
| 92582 | <1% | 1,329 | $142K | |
| 81003 | <1% | 51,292 | $130K | |
| 95716 | <1% | 36 | $115K | |
| 87081 | <1% | 12,870 | $107K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,058 | $105K |
| 31624 | <1% | 41 | $103K | |
| 94644 | <1% | 754 | $103K | |
| 96132 | <1% | 275 | $102K | |
| 90670 | <1% | 184 | $101K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,162 | $91K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 343 | $88K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,379 | $84K |
| 86850 | <1% | 597 | $81K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,299 | $80K |
| 17110 | <1% | 954 | $77K | |
| 92555 | <1% | 3,776 | $72K | |
| 94760 | <1% | 12,061 | $63K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 151 | $63K |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 3,406 | $56K |
| 96409 | <1% | 296 | $55K | |
| 51798 | <1% | 438 | $49K | |
| 96158 | <1% | 323 | $47K | |
| 96121 | <1% | 143 | $45K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,031 | $43K |
| 96136 | <1% | 203 | $43K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,290 | $38K |
| 77075 | <1% | 316 | $38K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $37K |
| 97760 | <1% | 885 | $37K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,729 | $37K |
| 96159 | <1% | 274 | $33K | |
| 77072 | <1% | 976 | $32K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $32K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,472 | $30K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,191 | $29K |
| 93886 | <1% | 100 | $27K | |
| 87581 | <1% | 886 | $25K | |
| 76000 | <1% | 485 | $22K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 841 | $21K |
| 72082 | <1% | 217 | $20K | |
| 99201 | <1% | 265 | $18K | |
| 83021 | <1% | 1,001 | $18K | |
| 97161 | <1% | 113 | $16K | |
| 92588 | <1% | 153 | $16K | |
| 88304 | <1% | 117 | $16K | |
| 88342 | <1% | 55 | $15K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,069 | $14K |
| 85045 | <1% | 3,408 | $14K | |
| 82947 | <1% | 3,058 | $14K | |
| 92552 | <1% | 212 | $13K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,178 | $13K |
| 93308 | <1% | 26 | $12K | |
| 93321 | <1% | 37 | $11K | |
| 87077 | <1% | 1,237 | $11K | |
| 74019 | <1% | 205 | $11K | |
| 82728 | <1% | 778 | $10K | |
| 81025 | <1% | 1,140 | $10K | |
| 86902 | <1% | 387 | $9K | |
| 81015 | <1% | 11,688 | $9K | |
| 83690 | <1% | 1,182 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 810 | $8K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 139 | $7K |
| 85046 | <1% | 1,055 | $7K | |
| 51741 | <1% | 26 | $7K | |
| 95700 | <1% | 16 | $7K | |
| 70360 | <1% | 161 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 897 | $6K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 24 | $6K |
| 31575 | <1% | 27 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 71 | $6K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 38 | $5K |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 66 | $5K |
| 29130 | <1% | 36 | $5K | |
| 97165 | <1% | 35 | $5K | |
| 0002A | <1% | 301 | $5K | |
| 88108 | <1% | 41 | $5K | |
| 93975 | <1% | 12 | $4K | |
| 80076 | <1% | 498 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 89 | $4K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 193 | $4K |
| 82805 | <1% | 72 | $4K | |
| 82803 | <1% | 172 | $4K | |
| 92553 | <1% | 50 | $3K | |
| 74455 | <1% | 30 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 12 | $3K |
| 85027 | <1% | 573 | $3K | |
| 72141 | <1% | 12 | $3K | |
| 80069 | <1% | 1,305 | $3K | |
| 83880 | <1% | 72 | $3K | |
| 0001A | <1% | 313 | $3K | |
| 87070 | <1% | 371 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 59 | $3K |
| 92630 | <1% | 29 | $3K | |
| 92593 | <1% | 25 | $3K | |
| 93788 | <1% | 14 | $2K | |
| 82977 | <1% | 328 | $2K | |
| 85007 | <1% | 621 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $2K |
| 36430 | <1% | 164 | $2K | |
| 83655 | <1% | 198 | $2K | |
| 84703 | <1% | 221 | $2K | |
| 82565 | <1% | 363 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 170 | $2K |
| 86900 | <1% | 588 | $2K | |
| 82247 | <1% | 413 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 48 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 48 | $2K |
| 93786 | <1% | 14 | $2K | |
| 83605 | <1% | 187 | $1K | |
| 76536 | <1% | 14 | $1K | |
| 73090 | <1% | 40 | $1K | |
| 84460 | <1% | 261 | $1K | |
| 87205 | <1% | 382 | $1K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 211 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 33 | $1K |
| 83735 | <1% | 721 | $1K | |
| 74220 | <1% | 12 | $1K | |
| 82150 | <1% | 178 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 943 | $1K |
| 82248 | <1% | 420 | $1K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 16 | $995.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 15 | $986.81 |
| 73521 | <1% | 24 | $975.86 | |
| 84484 | <1% | 76 | $960.22 | |
| 80061 | Lipid panel | <1% | 55 | $957.48 |
| 83615 | <1% | 148 | $914.88 | |
| 90461 | <1% | 563 | $831.69 | |
| 88313 | <1% | 12 | $824.84 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 785 | $795.11 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 55 | $785.24 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 19 | $775.54 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 18 | $762.42 |
| 73610 | <1% | 14 | $749.55 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 217 | $736.28 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 25 | $608.34 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 39 | $432.54 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 60 | $428.19 |
| V5020 | Conformity evaluation | <1% | 12 | $413.54 |
| S5010 | 5% dextrose and 0.45% normal saline, 1000 ml | <1% | 13 | $410.19 |
| 62270 | <1% | 41 | $367.31 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 109 | $367.18 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 16 | $364.04 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 94 | $339.89 |
| 82272 | <1% | 63 | $335.85 | |
| 82945 | <1% | 200 | $327.90 | |
| 84450 | <1% | 48 | $324.81 | |
| 82330 | <1% | 52 | $314.77 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 27 | $294.11 |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 26 | $293.56 |
| 85347 | <1% | 56 | $287.10 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 18 | $283.54 |
| 84466 | <1% | 17 | $275.99 | |
| 82570 | <1% | 108 | $264.34 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 24 | $228.92 |
| 86160 | <1% | 13 | $212.88 | |
| 85651 | <1% | 40 | $205.94 | |
| 87799 | <1% | 61 | $197.91 | |
| 87497 | <1% | 31 | $179.95 | |
| 83825 | <1% | 14 | $153.79 | |
| 82043 | <1% | 24 | $152.24 | |
| 83540 | <1% | 17 | $139.73 | |
| 87184 | <1% | 26 | $138.16 | |
| L3808 | Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment | <1% | 12 | $129.51 |
| 84157 | <1% | 40 | $120.96 | |
| 85610 | <1% | 48 | $119.52 | |
| 85730 | <1% | 26 | $106.05 | |
| 85018 | <1% | 67 | $104.60 | |
| 83970 | <1% | 97 | $104.04 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 12 | $100.89 |
| 80197 | <1% | 202 | $80.71 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 40 | $74.58 |
| 84550 | <1% | 13 | $68.24 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 119 | $67.20 |
| A4218 | Sterile saline or water, metered dose dispenser, 10 ml | <1% | 33 | $63.99 |
| 84295 | <1% | 22 | $61.17 | |
| 84132 | <1% | 22 | $60.59 | |
| 84156 | <1% | 16 | $47.37 | |
| 85008 | <1% | 845 | $12.70 | |
| 85014 | <1% | 22 | $12.49 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 117 | $2.33 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 38 | $0.00 |
| 83520 | 0% | 18 | $0.00 | |
| 83550 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRHOADES, CORY (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Cook Children's Medical Center | Fort Worth, TX | $21.29M |
| Cook Children's Medical Center | Mansfield, TX | $4.64M |
| Cook Children's Medical Center | Fort Worth, TX | $4.59M |
| Cook Children's Medical Center | Fort Worth, TX | $3.84M |
| Cook Children's Medical Center | Hurst, TX | $3.41M |
| Cook Children's Medical Center | Southlake, TX | $2.15M |
| Cook Children's Medical Center | Aledo, TX | $1.97M |
| Cook Children's Medical Center | Fort Worth, TX | $1.97M |
| Cook Childrens Medical Center - Prosper | Prosper, TX | $1.16M |
| Cook Children's Medical Center | Prosper, TX | $934K |
| Cook Children's Medical Center | Fort Worth, TX | $900K |
| Child Study Center | Fort Worth, TX | $117K |
| Cook Children's Medical Center | Fort Worth, TX | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.